Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 5/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 4/20 | 0.34 |
| ▸ | DNPEP | Q9ULA0 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.31 |
| ▸ | GABRD | O14764 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838139 | 0.88 | MEN1 (0.42) | CYP2D6CYP2C19KMT2AMEN1GAA | |
| SCHEMBL17632320 | 0.86 | DPP7 (0.40) | CYP2D6CYP2C19KMT2AMEN1GAA | |
| SCHEMBL354239 | 0.78 | CYP2D6 (0.50) | CYP2D6CYP2C19ALDH1A1MAPTPTGS1 | |
| SCHEMBL4885972 | 0.77 | CYP2D6 (0.38) | CYP2D6CYP2C19ANPEPDNPEPKMT2A | |
| SCHEMBL3600521 | 0.76 | — | — | |
| SCHEMBL4538408 | 0.76 | — | — | |
| SCHEMBL2556795 | 0.75 | CYP2D6 (0.37) | CYP2D6CYP2C19KMT2AMEN1GAA | |
| SCHEMBL22076985 | 0.75 | CYP2D6 (0.37) | CYP2D6CYP2C19KMT2AMEN1GAA | |
| Hydrochloric Acid SCHEMBL18342064 | 0.74 | GABRP (0.48) | CYP2D6CYP2C19ANPEPRNPEPDNPEP | |
| SCHEMBL23751418 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145913-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-115215807-A | Inhibition of OLIG2 activity | 科泰纳制药公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114306297-A | Proteasome inhibitors and uses thereof | 康奈尔大学 | 2022-04-12 | — | — | CN | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| CN-108351169-B | Proteasome inhibitors and uses thereof | 康奈尔大学 | 2022-01-28 | — | — | CN | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| EP-3504195-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| CN-109843868-A | inhibition of OLIG2 activity | 科泰纳制药公司 | 2019-06-04 | — | — | CN | disclosed |
| WO-2018039621-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-9678082-B2 | Method of traceless labeling glycoproteins on surface and application thereof | NATIONAL SUN YAT-SEN UNIVERSITY (TW) | 2017-06-13 | — | — | US | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7465736-B2 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | LABORATOIRES SERONO S.A. (CH) | 2008-12-16 | — | — | US | disclosed |
| WO-2007149456-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070185104-A1 | Benzoxazole acetonitriles | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-08-09 | — | — | US | disclosed |
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | MERCK SERONO SA (CH) | 2007-05-31 | — | — | US | disclosed |
| EP-1668004-A1 | BENZOXAZOLE ACETONITRILES | Applied Research Systems ARS Holding N.V. (AN) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005026159-A1 | BENZOXAZOLE ACETONITRILES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-03-24 | — | — | WO | disclosed |
| EP-0898596-B1 | SQUARATE DYES AND THEIR USE IN FLUORESCENT SEQUENCING METHOD | AMERSHAM PHARM BIOTECH UK LTD (GB) | 2001-08-29 | — | — | EP | disclosed |
| US-6140494-A | INCREASED WATER SOLUBILITY, INCREASED PHOTOSTABILITY, BRIGHTNESS AND THE POTENTIAL REDUCTION OF INTERACTIONS WITH SURROUNDINGS | AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | CYP2D6 4807/4885CYP2C19 4880/4885ANPEP 3608/4885 |
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | PRKACA, CSNK1A1, PRKACG | CYP2D6 1428/4885CYP2C19 709/4885ANPEP 2073/4885 |
| US-12145913-B2 | Inhibition of Olig2 activity | POU2F2, POU2F1, PLP2 | CYP2D6 4624/4885CYP2C19 4574/4885ANPEP 1615/4885 |
| US-11242323-B2 | Inhibition of OLIG2 activity | POU2F2, ING2, PAX2 | CYP2D6 4787/4885CYP2C19 4860/4885ANPEP 2924/4885 |
| US-20070185104-A1 | Benzoxazole acetonitriles | PKD1, PC, GPR119 | CYP2D6 58/4885CYP2C19 17/4885ANPEP 2251/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | CYP2D6 1020/4885CYP2C19 1430/4885ANPEP 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.